Erste Asset Management GmbH Increases Holdings in Replimune Group, Inc. $REPL

Erste Asset Management GmbH boosted its position in shares of Replimune Group, Inc. (NASDAQ:REPL) by 30.1% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 2,120,000 shares of the company’s stock after purchasing an additional 490,000 shares during the period. Erste Asset Management GmbH owned about 2.57% of Replimune Group worth $20,619,000 as of its most recent SEC filing.

Several other hedge funds also recently added to or reduced their stakes in REPL. Readystate Asset Management LP grew its holdings in Replimune Group by 1,296.2% during the 3rd quarter. Readystate Asset Management LP now owns 2,621,012 shares of the company’s stock valued at $10,982,000 after purchasing an additional 2,433,292 shares during the last quarter. Braidwell LP grew its holdings in Replimune Group by 550.3% during the 3rd quarter. Braidwell LP now owns 2,750,092 shares of the company’s stock valued at $11,523,000 after purchasing an additional 2,327,205 shares during the last quarter. Balyasny Asset Management L.P. grew its holdings in Replimune Group by 507.4% during the 3rd quarter. Balyasny Asset Management L.P. now owns 2,628,100 shares of the company’s stock valued at $11,012,000 after purchasing an additional 2,195,448 shares during the last quarter. JPMorgan Chase & Co. grew its holdings in Replimune Group by 2,333.6% during the 4th quarter. JPMorgan Chase & Co. now owns 925,173 shares of the company’s stock valued at $8,993,000 after purchasing an additional 887,157 shares during the last quarter. Finally, Jefferies Financial Group Inc. bought a new position in Replimune Group during the 4th quarter valued at about $6,942,000. 92.53% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

REPL has been the topic of several analyst reports. Wall Street Zen upgraded shares of Replimune Group from a “strong sell” rating to a “sell” rating in a report on Saturday, May 23rd. Weiss Ratings downgraded shares of Replimune Group from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Wednesday, June 3rd. Leerink Partners restated a “market perform” rating and issued a $2.00 target price (down from $11.00) on shares of Replimune Group in a research note on Monday, April 13th. HC Wainwright restated a “sell” rating on shares of Replimune Group in a research note on Monday, April 13th. Finally, BMO Capital Markets downgraded shares of Replimune Group from a “market perform” rating to an “underperform” rating in a research note on Monday, April 13th. Seven investment analysts have rated the stock with a Hold rating and three have given a Sell rating to the company. According to MarketBeat.com, Replimune Group currently has an average rating of “Reduce” and an average price target of $4.88.

Replimune Group Price Performance

Shares of REPL stock opened at $8.97 on Tuesday. The company has a debt-to-equity ratio of 0.33, a current ratio of 5.60 and a quick ratio of 5.60. The company has a market capitalization of $740.65 million, a P/E ratio of -2.61 and a beta of 0.88. The company’s 50-day simple moving average is $5.14 and its two-hundred day simple moving average is $7.27. Replimune Group, Inc. has a one year low of $1.50 and a one year high of $13.24.

Insider Activity

In other Replimune Group news, insider Christopher Sarchi sold 12,000 shares of the company’s stock in a transaction on Monday, June 1st. The stock was sold at an average price of $9.24, for a total transaction of $110,880.00. Following the completion of the sale, the insider owned 180,962 shares in the company, valued at $1,672,088.88. This represents a 6.22% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Corporate insiders own 5.20% of the company’s stock.

Replimune Group Profile

Replimune Group, Inc is a clinical‐stage biotechnology company focused on developing next‐generation oncolytic immunotherapies for the treatment of solid tumors. The company’s proprietary “RP” platform leverages genetically engineered herpes simplex virus type 1 (HSV-1) vectors armed with immunomodulatory payloads to selectively infect, replicate within and destroy cancer cells, while also stimulating systemic antitumor immune responses.

Replimune’s lead candidate, RP1, incorporates GM-CSF and a fusogenic protein to enhance both direct oncolysis and immune activation.